You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients

    SBC: Mercury Biomed LLC            Topic: 300

    Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury

    SBC: Allinaire Therapeutics, LLC            Topic: NHLBI

    Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: Bertec Corporation            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Enzymatic attachment of proteins to fluorescent nanodiamond surfaces.

    SBC: COLUMBUS NANOWORKS, INC.            Topic: 400

    Fluorescent nanodiamonds are biocompatibleinfinitely photostableand fluoresce in a variety of wavelengthsincluding the near infraredNIRregionThese characteristics suggest transformative applications in areas ranging from pure biological research to biomedical imagingwhere protein conjugated nanodiamonds could be targeted to specific tissues in living patients or even structures within individual c ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy

    SBC: HNB Therapeutics LLC            Topic: NIA

    Summary Glucocorticoid induced osteoporosis is the most common cause of secondary osteoporosisand the primary cause before ageIt affects overof the general populationwhereinare womenIn postmenopausal women and men agedand overtreatment would be recommended in at least half based on theAmerican College of Rheumatology guidelinesAdult stem cells are a promising class of regenerative cellssome lineag ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government